Swiss National Bank’s Anika Therapeutics ANIK Stock Holding History

Swiss National Bank’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-32,500	Closed	-$605K	–	2539
2023 Q3	$605K	Buy	32,500 +1,000	+3%	+$20.7K	﹤0.01%	2463
2023 Q2	$818K	Hold	31,500	–	–	﹤0.01%	2393
2023 Q1	$905K	Sell	31,500 -3,700	-11%	-$110K	﹤0.01%	2310
2022 Q4	$1.04M	Buy	35,200 +1,000	+3%	+$28.4K	﹤0.01%	2319
2022 Q3	$814K	Hold	34,200	–	–	﹤0.01%	2422
2022 Q2	$763K	Hold	34,200	–	–	﹤0.01%	2495
2022 Q1	$859K	Buy	34,200 +2,400	+8%	+$73.2K	﹤0.01%	2468
2021 Q4	$1.14M	Hold	31,800	–	–	﹤0.01%	2405
2021 Q3	$1.35M	Buy	31,800 +500	+2%	+$20.6K	﹤0.01%	2281
2021 Q2	$1.35M	Sell	31,300 -1,200	-4%	-$51.1K	﹤0.01%	2335
2021 Q1	$1.33M	Buy	32,500 +600	+2%	+$22.8K	﹤0.01%	2230
2020 Q4	$1.44M	Hold	31,900	–	–	﹤0.01%	2103
2020 Q3	$1.13M	Hold	31,900	–	–	﹤0.01%	2022
2020 Q2	$1.2M	Buy	31,900 +4,200	+15%	+$138K	﹤0.01%	1998
2020 Q1	$801K	Buy	27,700 +1,300	+5%	+$52.6K	﹤0.01%	1956
2019 Q4	$1.37M	Hold	26,400	–	–	﹤0.01%	1949
2019 Q3	$1.45M	Hold	26,400	–	–	﹤0.01%	1847
2019 Q2	$1.07M	Buy	26,400 +900	+4%	+$32.8K	﹤0.01%	2077
2019 Q1	$771K	Hold	25,500	–	–	﹤0.01%	2206
2018 Q4	$857K	Hold	25,500	–	–	﹤0.01%	2089
2018 Q3	$1.08M	Hold	25,500	–	–	﹤0.01%	2107
2018 Q2	$816K	Hold	25,500	–	–	﹤0.01%	2285
2018 Q1	$1.27M	Buy	25,500 +1,200	+5%	+$67.8K	﹤0.01%	1938
2017 Q4	$1.31M	Hold	24,300	–	–	﹤0.01%	1922
2017 Q3	$1.41M	Hold	24,300	–	–	﹤0.01%	1846
2017 Q2	$1.2M	Hold	24,300	–	–	﹤0.01%	1929
2017 Q1	$1.06M	Hold	24,300	–	–	﹤0.01%	1994
2016 Q4	$1.19M	Buy	24,300 +1,800	+8%	+$83.2K	﹤0.01%	1919
2016 Q3	$1.08M	Sell	22,500 -1,800	-7%	-$88.9K	﹤0.01%	1916
2016 Q2	$1.3M	Buy	24,300 +1,000	+4%	+$47.1K	﹤0.01%	1803
2016 Q1	$1M	Buy	23,300 +4,400	+23%	+$178K	﹤0.01%	1890
2015 Q4	$721K	Hold	18,900	–	–	﹤0.01%	2054
2015 Q3	$602K	Buy	18,900 +2,500	+15%	+$87.2K	﹤0.01%	2082
2015 Q2	$542K	Hold	16,400	–	–	﹤0.01%	2193
2015 Q1	$675K	Buy	16,400 +800	+5%	+$32.3K	﹤0.01%	2003
2014 Q4	$636K	Hold	15,600	–	–	﹤0.01%	2027
2014 Q3	$572K	Hold	15,600	–	–	﹤0.01%	2014
2014 Q2	$723K	Buy	15,600 +900	+6%	+$40K	﹤0.01%	1922
2014 Q1	$604K	Buy	14,700 +3,400	+30%	+$126K	﹤0.01%	2025
2013 Q4	$431K	Buy	+11,300	New	+$349K	﹤0.01%	2081

Other funds holding ANIK

Trigran Investments Northbrook, Illinois $418M AUM 3.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Swiss National Bank's ANIK Position: Q4 2023 in Review

Swiss National Bank sold out of Anika Therapeutics (ANIK) in Q4 2023, closing a stake of 32,500 shares — an estimated $605K sold.

Swiss National Bank first reported a position in ANIK in Q4 2013 and held it in 40 quarters. The position peaked at $1.45M in Q3 2019. 117 funds tracked by Wall St. Rank hold ANIK as of Q4 2023.

Swiss National Bank reported no remaining Anika Therapeutics position as of Q4 2023 after selling out during the quarter.
Swiss National Bank sold 32,500 Anika Therapeutics shares in Q4 2023, an estimated $605K.
Swiss National Bank first reported a position in Anika Therapeutics in Q4 2013 and held it in 40 quarters.
Swiss National Bank's Anika Therapeutics position peaked at $1.45M in Q3 2019.
117 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2023.

Based on Swiss National Bank's 13F filing for Q4 2023, filed 6 Feb 2024.